PriceTargets.com logo

Equillium - EQ Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 604.62%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.71 As of 11/15/2024 01:00 AM ET
▲ +0.03 (4.41%)

This chart shows the closing price for EQ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Equillium Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EQ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EQ

Analyst Price Target is $5.00
▲ +604.62% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Equillium in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 604.62% upside from the last price of $0.71.

This chart shows the closing price for EQ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Equillium. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
6/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
4/2/2024HC WainwrightBoost TargetBuy ➝ Buy$4.00 ➝ $5.00
12/26/2023HC WainwrightLower TargetBuy ➝ Buy$4.50 ➝ $4.00
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$5.50 ➝ $4.50
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.50
8/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$2.80
5/1/2023HC WainwrightLower Target$20.00 ➝ $5.50
3/24/2023Stifel NicolausLower TargetBuy$12.00 ➝ $7.00
2/8/2023Leerink PartnersLower TargetOutperform$12.00 ➝ $7.00
9/27/2022HC WainwrightBoost TargetBuy$15.00 ➝ $20.00
9/8/2022Leerink PartnersLower TargetOutperform$14.00 ➝ $12.00
5/23/2022HC WainwrightReiterated RatingBuy$15.00
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
3/25/2022Stifel NicolausReiterated RatingBuy$12.00
3/24/2022HC WainwrightBoost TargetBuy$12.00 ➝ $15.00
1/5/2022Leerink PartnersLower TargetOutperform$18.00 ➝ $14.00
12/2/2021Leerink PartnersReiterated RatingOutperform
11/15/2021HC WainwrightReiterated RatingBuy$12.00
10/29/2021Stifel NicolausInitiated CoverageBuy
10/18/2021Cantor FitzgeraldReiterated RatingOverweight
9/15/2021Cantor FitzgeraldInitiated CoverageOverweight$14.00
7/14/2021HC WainwrightReiterated RatingBuy$12.00
6/15/2021Leerink PartnersReiterated RatingBuy
5/18/2021Leerink PartnersReiterated RatingBuy$18.00
4/1/2021Leerink PartnersReiterated RatingBuy
3/3/2021JonestradingInitiated CoverageBuy$14.00
2/9/2021HC WainwrightReiterated RatingBuy$12.00
11/30/2020HC WainwrightLower TargetBuy$22.00 ➝ $12.00
11/30/2020HC WainwrightReiterated RatingHold ➝ Buy$22.00 ➝ $12.00
9/21/2020HC WainwrightReiterated RatingBuy$22.00
8/21/2020HC WainwrightLower TargetBuy$24.00 ➝ $22.00
8/13/2020Jefferies Financial GroupReiterated RatingBuy$16.00
8/10/2020Stifel NicolausReiterated RatingBuy$14.00
7/13/2020HC WainwrightReiterated RatingBuy$14.00 ➝ $24.00
7/13/2020Stifel NicolausReiterated RatingBuy$22.00 ➝ $10.00
5/26/2020HC WainwrightReiterated RatingBuy$14.00
5/19/2020HC WainwrightReiterated RatingBuy$14.00
3/27/2020HC WainwrightReiterated RatingBuy$14.00
1/2/2020Leerink PartnersReiterated RatingOutperform
12/30/2019HC WainwrightReiterated RatingBuy$14.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/21/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 1 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Equillium logo
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $0.71
Low: $0.66
High: $0.74

50 Day Range

MA: $0.91
Low: $0.68
High: $1.38

52 Week Range

Now: $0.71
Low: $0.48
High: $3.25

Volume

127,342 shs

Average Volume

311,327 shs

Market Capitalization

$25.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Equillium?

The following sell-side analysts have issued reports on Equillium in the last twelve months: HC Wainwright.
View the latest analyst ratings for EQ.

What is the current price target for Equillium?

0 Wall Street analysts have set twelve-month price targets for Equillium in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 604.6%. HC Wainwright has the highest price target set, predicting EQ will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Equillium in the next year.
View the latest price targets for EQ.

What is the current consensus analyst rating for Equillium?

Equillium currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EQ will outperform the market and that investors should add to their positions of Equillium.
View the latest ratings for EQ.

What other companies compete with Equillium?

Other companies that are similar to Equillium include Kezar Life Sciences, Anixa Biosciences, FibroBiologics, Adagene and Monopar Therapeutics. Learn More about companies similar to Equillium.

How do I contact Equillium's investor relations team?

Equillium's physical mailing address is 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037. The company's listed phone number is (858) 240-1200 and its investor relations email address is [email protected]. The official website for Equillium is equilliumbio.com. Learn More about contacing Equillium investor relations.